---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-23-000010"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:50:55.335116+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics reports FY2022 financial results and provides business update

## Summary
- Net loss for FY2022 was $54.2 million, including $30.4 million non-routine merger-related IPR&D expense.
- Cash, cash equivalents and marketable securities totaled $69.2 million as of December 31, 2022.
- LSTA1 Phase 2b ASCEND study in pancreatic cancer is ongoing; basket trial in other solid tumors planned for H1 2023.
- HONEDRA for critical limb ischemia is in pre-consultation with Japan's PMDA; partner search continues.
- XOWNA development suspended; LSTA201 proof-of-concept study did not show consistent kidney function improvement.

## SEC filing metadata
- accession: 0000320017-23-000010
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001723000010/0000320017-23-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001723000010/clbs-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-23-000010
- JSON: https://secwatch.observer/filing/0000320017-23-000010.json
- Plain text: https://secwatch.observer/filing/0000320017-23-000010.txt

## Key facts
- Earnings Releases
  LISATA THERAPEUTICS, INC. reported financial results for three and twelve months ended December 31, 2022.
  - Period: three and twelve months ended December 31, 2022
  - Result: reported results
  source text: Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, NJ (March 30, 2023) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three and twelve months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001723000010/0000320017-23-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.